http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006025343-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0fc19d8d6ba9ad5c1fa5770341472b56 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1825 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-726 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| filingDate | 2005-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ebdb5e4f336690de79dda74a4d62e991 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f201b1132dbdadf54600919688566713 |
| publicationDate | 2006-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2006025343-A1 |
| titleOfInvention | Angiogenically effective unit dose fo FGF and method of adminstering |
| abstract | The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose comprising 0.2 μg/kg to 36 μg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. In another aspect, the present invention is directed to a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Typically, the angiogenically effective dose comprises 0.2 μg/kg to 36 μg/kg of an FGF of any one of SEQ ID NOS:1-3, 5, 8-10, or 12-14 or an angiogenically active fragment or mutein thereof. In yet another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF of any one of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007135348-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010303793-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011105400-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7541337-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008113916-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008031970-A1 |
| priorityDate | 1998-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 278.